156 related articles for article (PubMed ID: 16397290)
1. Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe.
Park JY; Kim KA; Park PW; Ha JM
J Clin Pharmacol; 2006 Jan; 46(1):109-14. PubMed ID: 16397290
[TBL] [Abstract][Full Text] [Related]
2. Impaired 6-hydroxychlorzoxazone elimination in patients with kidney disease: Implication for cytochrome P450 2E1 pharmacogenetic studies.
Nolin TD; Gastonguay MR; Bies RR; Matzke GR; Frye RF
Clin Pharmacol Ther; 2003 Dec; 74(6):555-68. PubMed ID: 14663458
[TBL] [Abstract][Full Text] [Related]
3. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans.
Poloyac SM; Tosheva RT; Gardner BM; Shedlofsky SI; Blouin RA
Clin Pharmacol Ther; 1999 Dec; 66(6):554-62. PubMed ID: 10613610
[TBL] [Abstract][Full Text] [Related]
4. Urinary excretion of 6-hydroxychlorzoxazone as an index of CYP2E1 activity.
Dreisbach AW; Ferencz N; Hopkins NE; Fuentes MG; Rege AB; George WJ; Lertora JJ
Clin Pharmacol Ther; 1995 Nov; 58(5):498-505. PubMed ID: 7586943
[TBL] [Abstract][Full Text] [Related]
5. [Changes of CYP2E1 activity in diabetic rat model].
Li L; Zhang Y
Yao Xue Xue Bao; 1998 Dec; 33(12):891-5. PubMed ID: 12016852
[TBL] [Abstract][Full Text] [Related]
6. Circadian rhythm of cytochrome P4502E1 and its effect on disposition kinetics of chlorzoxazone in rats.
Khemawoot P; Nishino K; Ishizaki J; Yokogawa K; Miyamoto K
Eur J Pharmacol; 2007 Nov; 574(1):71-6. PubMed ID: 17651723
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers.
Eap CB; Schnyder C; Besson J; Savary L; Buclin T
Clin Pharmacol Ther; 1998 Jul; 64(1):52-7. PubMed ID: 9695719
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus.
Ahn CY; Bae SK; Jung YS; Lee I; Kim YC; Lee MG; Shin WG
Drug Metab Dispos; 2008 Jul; 36(7):1233-41. PubMed ID: 18378564
[TBL] [Abstract][Full Text] [Related]
9. Hepatic cytochrome P450 2E1 activity in nonalcoholic fatty liver disease.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2008 May; 91(5):733-8. PubMed ID: 18672640
[TBL] [Abstract][Full Text] [Related]
10. Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans.
Emery MG; Jubert C; Thummel KE; Kharasch ED
J Pharmacol Exp Ther; 1999 Oct; 291(1):213-9. PubMed ID: 10490907
[TBL] [Abstract][Full Text] [Related]
11. In vivo CYP2E1 phenotyping as a new potential biomarker of occupational and experimental exposure to benzene.
Piccoli P; Carrieri M; Padovano L; Di Mare M; Bartolucci GB; Fracasso ME; Lepera JS; Manno M
Toxicol Lett; 2010 Jan; 192(1):29-33. PubMed ID: 19900514
[TBL] [Abstract][Full Text] [Related]
12. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
13. Obesity-induced increase of CYP2E1 activity and its effect on disposition kinetics of chlorzoxazone in Zucker rats.
Khemawoot P; Yokogawa K; Shimada T; Miyamoto K
Biochem Pharmacol; 2007 Jan; 73(1):155-62. PubMed ID: 17049493
[TBL] [Abstract][Full Text] [Related]
14. A study on the pharmacokinetics of chlorzoxazone in healthy Thai volunteers.
Prompila N; Wittayalertpanya S; Komolmit P
J Med Assoc Thai; 2007 Jan; 90(1):160-6. PubMed ID: 17621748
[TBL] [Abstract][Full Text] [Related]
15. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats.
Rockich K; Blouin R
Drug Metab Dispos; 1999 Sep; 27(9):1074-7. PubMed ID: 10460809
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress.
Leclercq I; Desager JP; Horsmans Y
Clin Pharmacol Ther; 1998 Aug; 64(2):144-9. PubMed ID: 9728894
[TBL] [Abstract][Full Text] [Related]
17. Development of a non-high pressure liquid chromatography assay to determine [14C]chlorzoxazone 6-hydroxylase (CYP2E1) activity in human liver microsomes.
Draper AJ; Madan A; Latham J; Parkinson A
Drug Metab Dispos; 1998 Apr; 26(4):305-12. PubMed ID: 9531516
[TBL] [Abstract][Full Text] [Related]
18. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent effects of Klebsiella pneumoniae endotoxin on the pharmacokinetics of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, in rats: restoration of the parameters in 96 hour in KPLPS rats to control levels.
Jung HY; Kang HE; Choi YH; Kim SH; Lee MG
Biopharm Drug Dispos; 2009 Nov; 30(8):485-93. PubMed ID: 19753555
[TBL] [Abstract][Full Text] [Related]
20. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure.
Frye RF; Adedoyin A; Mauro K; Matzke GR; Branch RA
J Clin Pharmacol; 1998 Jan; 38(1):82-9. PubMed ID: 9597564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
